CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Brazil

2017-06-09
Price :
Published : Jun-2017
No. of Pages : 199

Brazil has one of the fastest growing pharmaceutical markets in the world. It is driven by an increasing disease burden and high affordability. However, a decrease in foreign investment and increased government promotion of generic drugs are barriers to growth. The value of the market was US$25.3 Billion in 2016, having increased from US$15.4 Billion in 2009 at a Compound Annual Growth Rate (CAGR) of 3.4%. Changing demographics are an important driver for the market, as the increasingly elderly population will lead to an increase in the incidence of chronic and other lifestyle-associated diseases. The growing middle class, who have high purchasing power, is another major driver.

Brazil’s medical device market was valued at US$7.1 Billion in 2009 and US$9.7 Billion in 2016. It is projected to grow at a CAGR of 6.4% from US$10.9 Billion in 2017 to US$14 Billion in 2021. In 2016, In Vitro Diagnostics (IVD) accounted for 11.5% of the medical device market, followed by orthopedic devices (10.8%), diagnostic imaging (10.6%), ophthalmic devices (8.8%) and cardiovascular devices (8.7%).

Most hospitals in Brazil offer primary care services exclusively. In 2016, health expenditure accounted for 8.2% of GDP, having accounted for 8.6% in 2009. Brazilian hospitals have inadequate resources and are thereby unable to provide access to healthcare provisions for every citizen, especially to those in weaker economic sections.

Brazil entered a period of recession in 2015. The economy contracted by 3.6% in 2016. This was due to a fall in commodity prices and political instability that led to a decline in investor confidence. This was augmented by the Chinese economic slowdown, which led to reduced demand for commodities and the corruption scandals involving government officials and major companies. In August 2016, following mass nationwide protests, President Rousseff was impeached on charges of breaking budgetary laws and the incumbent vice president Michel Temer took over.

The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Brazil” an overview of the pharmaceutical and medical device market of Brazil, including the market size; market segmentation by generic, Over-The-Counter (OTC), biologic and biosimilar products; and the key drivers and barriers for the market.

In depth, this report provides the following analysis –

  • Covers the country’s reimbursement and payer landscape, as well as the regulatory landscape. The reimbursement and payer landscape section elaborates on the features of the healthcare reimbursement process for Brazil.
  • Provides a detailed analysis of the political and economic environment of Brazil. It analyzes its economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
  • Provides an overview of the opportunities and challenges for growth that exist in the healthcare market of Brazil.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Brazil, and includes –

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Hypermarcas, Roche, Novartis and Sanofi and Profiles and SWOT analyses of the major players in the medical device market: Johnson & Johnson, B.Braun, Medtronic, Baxter and GSK.
  • An insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the country’s political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Brazil healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to –

  • Develop business strategies by understanding the trends shaping and driving Brazil’s healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Brazil’s healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership
Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Company Profile: 23andMe

Company Profile: 23andMe Summary 23andMe is a personal genomics and biotechnology company that leverages machine learning technology to provide DNA analysis services. It also offers web-based interactive tools to individuals, helping them understand their own genetics information. Scope The report provides information and insights into 23andMe, including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into 23andMe's business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success ......
$350

Company Profile: Fitbit, Inc.

Company Profile: Fitbit, Inc. Summary Fitbit, Inc. (Fitbit) offers a range of connected health and fitness devices that monitors various health parameters like sleep duration, heart rate, BMI, calories burned, exercise routines, etc. Scope The report provides information and insights into Fitbit, Inc., including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into Fitbit business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success factors.......
$350

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – India

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in India. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of India. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

The State of the Microbiome

The State of the Microbiome Summary GlobalData's "The State of the Microbiome", report provides an assessment of how the pharmaceutical industry perceives the state of the microbiome, including the challenges associated with developing, launching, and manufacturing microbiome therapeutics as well as where opportunity remains to invest in the microbiome space. Scope - Microbiome investment - determine level of activity and investment in the development of microbiome therapeutics by therapy area - Identify the challenges associated with - Developing microbiome therapeutics - Launching microbiome therapeutics - Manufacturing microbiome therapeutics. Reasons to buy - Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with devel......
$1495

Rheumatoid Arthritis: Epidemiology Forecast to 2027

Rheumatoid Arthritis: Epidemiology Forecast to 2027 Summary Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the body's immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life. GlobalData epidemiologists used sources that provided the diagnosed incidence, diagnosed prevalence, and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06. In 2......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2018

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018 Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2018. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informati......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Cataract Global Clinical Trials Review, H2, 2018

Cataract Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Cataract Global Clinical Trials Review, H2, 2018" provides an overview of Cataract clinical trials scenario. This report provides top line data relating to the clinical trials on Cataract. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated......
$2500

Choroidal Neovascularization Global Clinical Trials Review, H2, 2018

Choroidal Neovascularization Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Choroidal Neovascularization Global Clinical Trials Review, H2, 2018" provides an overview of Choroidal Neovascularization clinical trials scenario. This report provides top line data relating to the clinical trials on Choroidal Neovascularization. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary......
$2500

Chemotherapy Induced Anemia Global Clinical Trials Review, H2, 2018

Chemotherapy Induced Anemia Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Chemotherapy Induced Anemia Global Clinical Trials Review, H2, 2018" provides an overview of Chemotherapy Induced Anemia clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Anemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary dat......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy